| |
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about the latest innovations in packaging and aseptic filling solutions that meet the complex demands of emerging therapies. Discover how to ensure product integrity, safety and efficiency. Register now. 
|
|
Today’s Big NewsJan 14, 2025 |
|
Connecting the Innovation Districts in Cincinnati, Columbus and Cleveland, the Ohio Discovery Corridor drives opportunity, innovation, and collaboration unlike anywhere else in the Midwest. Explore the corridor. 
|
|
| By Angus Liu Roche has about $10 billion in M&A firepower it can deploy every year, but it’s “not just going to spend money,” the company’s pharma CEO Teresa Graham said at the J.P. Morgan Healthcare Conference. |
|
|
|
By James Waldron The release name-checked UB-VV400, an off-the-shelf, multidomain fusion protein surface-engineered lentiviral vector designed to generate CD22-directed CAR-T cells within a patient’s body. |
By Nick Paul Taylor Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease trial, teeing the biotech up to run a confirmatory study of its ex-Astellas asset. But a cross-trial comparison suggests Amgen’s blockbuster may have the advantage on the efficacy front. |
By James Waldron With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets. |
|
Researchers must navigate complex regulations to ensure compliance. Join BioIVT’s experts for an insightful webinar discussing important regulations and considerations... Watch Now >> 
|
|
By Ben Adams,Gabrielle Masson,James Waldron,Darren Incorvaia Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. Yesterday saw some high-value dealmaking, including one of the biggest acquisitions in recent JPM memory, when Johnson & Johnson snapped up neuro biopharma Intra-Cellular for a cool $14.6 billion. |
By Darren Incorvaia Spanish pharma giant Grifols is leveraging its massive collection of plasma samples to look for early biomarkers of Parkinson’s disease (PD) thanks to a $21 million grant from the Michael J. Fox Foundation for Parkinson’s Research. |
By Eric Sagonowsky Each year at the J.P. Morgan Healthcare Conference, pharma CEOs are tasked with assuring and convincing investors that they’ve positioned their companies to overcome expected challenges. Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on. |
By Conor Hale SAN FRANCISCO—The CE mark allows the company to begin rolling out the treatment immediately, essentially as a software update, to current patients who have already received its Percept neurostimulator implants equipped with BrainSense technology. |
By Anastassia Gliadkovskaya As deadly fires continue to rage in Los Angeles, healthcare companies far and wide are stepping up to serve those affected. At least 24 people have died from the fires and dozens remain missing. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we dive into 2024's batch of new FDA drug approvals, highlighting some potential blockbusters and shifts from previous years' lists. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
